Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cogent Biosciences (COGT)
NASDAQ:COGT
Holding COGT?
Track your performance easily
COGT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.28 - $12.61
Previous Close$7.84
Volume2.67M
Average Volume (3M)1.38M
Market Cap
$861.60M
Enterprise Value$543.91M
Total Cash (Recent Filing)$335.52M
Total Debt (Recent Filing)$17.83M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Mar 18, 2025EPS Estimate
-$0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.48
Shares Outstanding110,461,729
10 Day Avg. Volume2,363,641
30 Day Avg. Volume1,375,732
Standard Deviation0.66
R-Squared0.02
Alpha0.07
Financial Highlights & Ratios
Price to Book (P/B)3.35
Price to Sales (P/S)906.95
Price to Cash Flow (P/CF)-4.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue572.54
Enterprise Value/Gross Profit572.54
Enterprise Value/Ebitda-2.22
Forecast
1Y Price Target
$17.00Price Target Upside116.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Cogent Biosciences News
PremiumCompany Announcements
Cogent Biosciences Reports Progress in Clinical Trials and Financial Standing
Bulls Say, Bears Say
Bulls Say
Financial PositionCogent has a strong cash position of $346M which can fund operations into late 2026.
Market OpportunityThe results continue to support that bezuclastinib has a differentiated profile within SM that could allow for a relevant market opportunity to be captured in this estimated >$2Bn market.
Safety And EfficacyThe clinical profile for Bezu looks better on both efficacy and safety compared to Ayvakit in ASM.
Bears Say
Competitive LandscapeBoth OKI-219 and Scorpion's STX-478 appear to have greater in vivo anti-tumor efficacy compared to CGT6297.
Safety ConcernsConcerns have been raised regarding the utilization of Bezuclastinib in non-advanced systemic mastocytosis due to its less favorable safety profile compared to Ayvakit.
Stock PerformanceCogent stock has traded off nearly -20% based on data disclosures that have largely been known since last year.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
COGT FAQ
What was Cogent Biosciences’s price range in the past 12 months?
Cogent Biosciences lowest stock price was $4.28 and its highest was $12.61 in the past 12 months.
What is Cogent Biosciences’s market cap?
Currently, no data Available
When is Cogent Biosciences’s upcoming earnings report date?
Cogent Biosciences’s upcoming earnings report date is Mar 18, 2025 which is in 87 days.
How were Cogent Biosciences’s earnings last quarter?
Cogent Biosciences released its earnings results on Nov 12, 2024. The company reported -$0.64 earnings per share for the quarter, missing the consensus estimate of -$0.566 by -$0.074.
Is Cogent Biosciences overvalued?
According to Wall Street analysts Cogent Biosciences’s price is currently Undervalued.
Does Cogent Biosciences pay dividends?
Cogent Biosciences does not currently pay dividends.
What is Cogent Biosciences’s EPS estimate?
Cogent Biosciences’s EPS estimate is -$0.59.
How many shares outstanding does Cogent Biosciences have?
Cogent Biosciences has 110,461,730 shares outstanding.
What happened to Cogent Biosciences’s price movement after its last earnings report?
Cogent Biosciences reported an EPS of -$0.64 in its last earnings report, missing expectations of -$0.566. Following the earnings report the stock price went down -0.192%.
Which hedge fund is a major shareholder of Cogent Biosciences?
Among the largest hedge funds holding Cogent Biosciences’s share is Fairmount Funds Management Llc. It holds Cogent Biosciences’s shares valued at 67M.
---
Cogent Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.00 (116.84% Upside)
$17.00 (116.84% Upside)
Hedge Fund Trend
Decreased
By 450.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 5.8%
Last 30 Days ▼ 5.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
51.93%
12-Months-Change
Fundamentals
Return on Equity
-78.47%
Trailing 12-Months
Asset Growth
8.04%
Trailing 12-Months
Company Description
Cogent Biosciences
Unum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.
---
COGT Stock 12 Month Forecast
Average Price Target
$17.00
▲(116.84% Upside)
Technical Analysis
Best Analysts Covering COGT
1 Year
1 Year Success Rate
5/12 ratings generated profit
1 Year Average Return
-0.79%
reiterated a buy rating 11 days ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 41.67% of your transactions generating a profit, with an average return of -0.79% per trade.
---